H. Mäkelä
5 Papers
41 Citations
H. Mäkelä is an academic researcher. The author has contributed to research in topics: Combination chemotherapy & Melphalan. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma
I. P. Palva,P. Ahrenberg,K. Ala Harja,A. Almqvist,Erkki Elonen,Heikki Hallman,A. Hänninen,M. Ilvonen,B. Isomaa,J. Jouppila,E. Järvenpää,G. Järventie,H. Kilpi,E. Koivunen,K. Kätkä,M. Kááriáinen,Reino Lahtinen,A. Laitinen,M. Lehtinen,H. Mäkelä,P. Nyländen,D. Nyman,T. Oivanen,S. Pakkala,T-T. Pelliniemi,T. Pulli,Allan Rajamäki,Tapani Ruutu,J. Savola,K. Soininen,Tuomo Timonen,C. Wasastjerna,Juhani Vilpo +32 more
TL;DR: 94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines, and only 10 responders among the 81 patients with longer previous chemotherapy responded.
18
Aggressive combination chemotherapy in multiple myeloma. A multicentre trial
I. P. Palva,P. Ahrenberg,A. Almquist,Ala-Harja K,J. Apajalahti,Heikki Hallman,A. Hänninen,M. Ilvonen,E. Järvenpää,G. Järventie,H. Kilpi,S. Koistinen,E. Koivunen,E. Korpi,K. Kätkä,Reino Lahtinen,A. Laitinen,M. Lehtinen,H. Mäkelä,T. Oivanen,Tarja-Terttu Pelliniemi,T. Pulli,S. Rosengård,A. Rajamäki,J. Tiilikaninen,Tuomo Timonen,E. Waris,C. Wasastjerna,Juhani Vilpo +28 more
TL;DR: A one-armed multicentre trial was conducted in Finland to document the possible beneficial effect of aggressive combination chemotherapy MOCCA on the remission induction and survival in multiple myeloma.
16
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma
I. P. Palva,Ala-Harja K,A. Almqvist,Erkki Elonen,Heikki Hallman,A. Hänninen,M. Ilvonen,B. Isomaa,J. Jouppila,E. Järvenpää,G. Järventie,H. Kilpi,Pirjo Koistinen,E. Koivunen,K. Kätkä,M. Kááriáinen,R. Lahtinen,A. Laitinen,M. Lehtinen,H. Mäkelä,P. Nyländen,D. Nyman,T. Oivanen,Tarja-Terttu Pelliniemi,T. Pulli,A. Rajamäki,Kari Remes,S. Rosengård,Tapani Ruutu,K. Soininen,T. Timonen,C. Wasastjerna,Juhani Vilpo,Liisa Volin +33 more
TL;DR: It is concluded that, in multidrug therapies, the continuation of corticosteroid at conventional dosage beyond the first course does not improve response rate or survival time in multiple myeloma.
8
Effect of the Choice of Primary Chemotherapy on the Cumulative Length of Stay in Hospital for Multiple Myeloma.
Ilmari Palva,P. Ahrenberg,K. Ala-harja,A. Almqvist,H. Hallman,A. Hävninen,M. Ilvonen,B. Isomaa,J. Jouppila,E. Järvenpää,H. Kilpi,S. Koistinen,E. Koivunen,K. Kätkä,Reino Lahtinen,A. Laitinen,H. Mäkelä,P. Nyländen,T. Oivanen,T. Pijlli,K. Soininen,E. Waris,C. Wasastjerna +22 more
TL;DR: It seems that the need for inpatient care for patients with multiple myeloma is mostly related to the complications of the disease itself and to intercurrent disorders including infections.
Effect of the Choice of Primairy Chemotherapy on the Cumula.tj.ve Length of Stay in Hiospital fOr Multiple Myeloma
I. P. Palva,Ahrenberg P,K. Ala-harja,A. Al,H. Wallman,A. Haivninen,M. Ilvonen,B. Isomaa,J. Jouppila,E. Järvenpää,S. Koistinen,E. Koivunen,K. Katka,R. Lahtinen,A. Laitinen,H. Mäkelä,P. Nyländen,T. Oivanen,T. Pijlli,K. Soininen,E. Waris,C. Wasastjerna +21 more
- 01 Jan 1990
TL;DR: It seems that the need for inpatient care for patients with multiple myeloma is mostly related to the complications of the disease itself and to intercurrent disorders including infections.